Trevi Therapeutics, Inc. (TRVI) Institutional Ownership

Ownership Summary

Recent 13F filings as of September 2025 show that 165 institutional investors hold a position in Trevi Therapeutics, Inc. (NASDAQ:TRVI).

• Institutional ownership in Trevi Therapeutics edged down to 108.2% in September 2025, compared to 112.0% in June 2025.
• On a quarter-over-quarter basis, institutional holdings shifted by 16.05%, with a year-over-year an increase of 79.35% in the count of filers.
• During the quarter, 98 institutions bought more Trevi Therapeutics shares, 46 sold shares, and 21 of the 165 total investors held their position steady.
• The total number of shares held by institutions in Trevi Therapeutics increased to 131.77Mn as of September 2025, a net change of up by 18.22Mn shares quarter on quarter, and up 74.85Mn shares year over year.
• With 13.22Mn shares, NEA Management Company, LLC commands the largest institutional position in Trevi Therapeutics as of September 30, 2025, equating to 10.86% of the company.
• Among the most significant buyers of Trevi Therapeutics during September 2025 were VIKING GLOBAL INVESTORS LP (3.59Mn), MORGAN STANLEY (3.28Mn), WELLINGTON MANAGEMENT GROUP LLP (3.08Mn), FMR LLC (2.93Mn), Artia Global Partners LP (2.69Mn).
• Leading sellers of Trevi Therapeutics stock in September 2025 included Woodline Partners LP (3.95Mn), BALYASNY ASSET MANAGEMENT L.P. (1.73Mn), Siren, L.L.C. (1.40Mn), CITADEL ADVISORS LLC (1.13Mn), Octagon Capital Advisors LP (857.00K).
• The top 10 institutional holders of Trevi Therapeutics for the quarter ending September 2025 included NEA Management Company, LLC (13.22Mn), Frazier Life Sciences Management, L.P. (10.26Mn), BlackRock, Inc. (9.90Mn), Rubric Capital Management LP (8.53Mn), VANGUARD GROUP INC (5.83Mn), VIKING GLOBAL INVESTORS LP (5.13Mn), Vivo Capital, LLC (5.09Mn), MARSHALL WACE, LLP (4.84Mn), MORGAN STANLEY (4.30Mn), ALLIANCEBERNSTEIN L.P. (4.29Mn).